CTLT Loading...

From TMO earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Oct 22 ◎
Mark Masper CEO, Thermo Fisher Scientific Inc TMO Q3 FY25 call
Pharma customers are actively reshoring manufacturing to the U.S., creating near-term construction/equipment demand and long-term recurring consumables growth for Thermo Fisher. — Steers large pharma spending toward Thermo Fisher's U.S. sites and could shift market share from European CDMOs.
CTLT
MED

About CTLT Analyst Coverage

Buzzberg tracks CTLT across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Mark Masper.